125 related articles for article (PubMed ID: 19179773)
1. Long-term epoprostenol therapy in pulmonary artery hypertension.
Sakuma M; Demachi J; Nawata J; Suzuki J; Takahashi T; Shirato K
Circ J; 2009 Mar; 73(3):523-9. PubMed ID: 19179773
[TBL] [Abstract][Full Text] [Related]
2. Use of aerosolized inhaled epoprostenol in the treatment of portopulmonary hypertension.
Schroeder RA; Rafii AA; Plotkin JS; Johnson LB; Rustgi VK; Kuo PC
Transplantation; 2000 Aug; 70(3):548-50. PubMed ID: 10949204
[TBL] [Abstract][Full Text] [Related]
3. Epoprostenol (prostacyclin) therapy in HIV-associated pulmonary hypertension.
Aguilar RV; Farber HW
Am J Respir Crit Care Med; 2000 Nov; 162(5):1846-50. PubMed ID: 11069824
[TBL] [Abstract][Full Text] [Related]
4. Successful use of continuous intravenous prostacyclin in a patient with severe portopulmonary hypertension.
Kähler CM; Graziadei I; Wiedermann CJ; Kneussl MP; Vogel W
Wien Klin Wochenschr; 2000 Jul; 112(14):637-40. PubMed ID: 11008327
[TBL] [Abstract][Full Text] [Related]
5. Acute effects of sildenafil in patients with primary pulmonary hypertension receiving epoprostenol.
Kuhn KP; Wickersham NE; Robbins IM; Byrne DW
Exp Lung Res; 2004 Mar; 30(2):135-45. PubMed ID: 14972773
[TBL] [Abstract][Full Text] [Related]
6. Hemodynamic effects of epoprostenol in patients with systemic sclerosis and pulmonary hypertension.
Strange C; Bolster M; Mazur J; Taylor M; Gossage JR; Silver R
Chest; 2000 Oct; 118(4):1077-82. PubMed ID: 11035680
[TBL] [Abstract][Full Text] [Related]
7. Aerosolised iloprost improves pulmonary haemodynamics in patients with primary pulmonary hypertension receiving continuous epoprostenol treatment.
Petkov V; Ziesche R; Mosgoeller W; Schenk P; Vonbank K; Stiebellehner L; Raderer M; Brunner C; Kneussl M; Block LH
Thorax; 2001 Sep; 56(9):734-6. PubMed ID: 11514696
[TBL] [Abstract][Full Text] [Related]
8. Long-term follow-up after conversion from intravenous epoprostenol to oral therapy with bosentan or sildenafil in 13 patients with pulmonary arterial hypertension.
Johnson RF; Loyd JE; Mullican AL; Fink CA; Robbins IM
J Heart Lung Transplant; 2007 Apr; 26(4):363-9. PubMed ID: 17403478
[TBL] [Abstract][Full Text] [Related]
9. Central venous blood oxygen saturation monitoring in patients with chronic pulmonary arterial hypertension treated with continuous IV epoprostenol: correlation with measurements of hemodynamics and plasma brain natriuretic peptide levels.
Chin KM; Channick RN; Kim NH; Rubin LJ
Chest; 2007 Sep; 132(3):786-92. PubMed ID: 17646224
[TBL] [Abstract][Full Text] [Related]
10. Intravenous epoprostenol in inoperable chronic thromboembolic pulmonary hypertension.
Cabrol S; Souza R; Jais X; Fadel E; Ali RH; Humbert M; Dartevelle P; Simonneau G; Sitbon O
J Heart Lung Transplant; 2007 Apr; 26(4):357-62. PubMed ID: 17403477
[TBL] [Abstract][Full Text] [Related]
11. Long-term treatment of primary pulmonary hypertension with continuous intravenous epoprostenol (prostacyclin).
Higenbottam T; Wheeldon D; Wells F; Wallwork J
Lancet; 1984 May; 1(8385):1046-7. PubMed ID: 6143976
[TBL] [Abstract][Full Text] [Related]
12. Primary pulmonary hypertension: improved long-term effects and survival with continuous intravenous epoprostenol infusion.
Shapiro SM; Oudiz RJ; Cao T; Romano MA; Beckmann XJ; Georgiou D; Mandayam S; Ginzton LE; Brundage BH
J Am Coll Cardiol; 1997 Aug; 30(2):343-9. PubMed ID: 9247503
[TBL] [Abstract][Full Text] [Related]
13. Acute hemodynamic effects of intravenous adenosine in patients with associated pulmonary arterial hypertension: Comparison with intravenous epoprostenol.
Rossi R; Coppi F; Sgura F; Monopoli D; Boriani G
Pulm Pharmacol Ther; 2018 Apr; 49():147-151. PubMed ID: 28642014
[TBL] [Abstract][Full Text] [Related]
14. Vasodilator therapy after heart transplantation: effects of inhaled nitric oxide and intravenous prostacyclin, prostaglandin E1, and sodium nitroprusside.
Kieler-Jensen N; Lundin S; Ricksten SE
J Heart Lung Transplant; 1995; 14(3):436-43. PubMed ID: 7654728
[TBL] [Abstract][Full Text] [Related]
15. Weaning and discontinuation of epoprostenol in children with idiopathic pulmonary arterial hypertension receiving concomitant bosentan.
Ivy DD; Doran A; Claussen L; Bingaman D; Yetman A
Am J Cardiol; 2004 Apr; 93(7):943-6. PubMed ID: 15050507
[TBL] [Abstract][Full Text] [Related]
16. The effects of chronic prostacyclin therapy on cardiac output and symptoms in primary pulmonary hypertension.
Rich S; McLaughlin VV
J Am Coll Cardiol; 1999 Oct; 34(4):1184-7. PubMed ID: 10520810
[TBL] [Abstract][Full Text] [Related]
17. Prostacyclin and milrinone by aerosolization improve pulmonary hemodynamics in newborn lambs with experimental pulmonary hypertension.
Kumar VH; Swartz DD; Rashid N; Lakshminrusimha S; Ma C; Ryan RM; Morin FC
J Appl Physiol (1985); 2010 Sep; 109(3):677-84. PubMed ID: 20616229
[TBL] [Abstract][Full Text] [Related]
18. Low-dose systemic phosphodiesterase inhibitors amplify the pulmonary vasodilatory response to inhaled prostacyclin in experimental pulmonary hypertension.
Schermuly RT; Ghofrani HA; Enke B; Weissmann N; Grimminger F; Seeger W; Schudt C; Walmrath D
Am J Respir Crit Care Med; 1999 Nov; 160(5 Pt 1):1500-6. PubMed ID: 10556112
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of acute inhalation of nitric oxide in patients with primary pulmonary hypertension using chronic use of continuous epoprostenol infusion.
Saji K; Sakuma M; Suzuki J; Takahashi T; Demachi J; Nawata J; Kitamukai O; Onoue N; Sugimura K; Tada T; Fukui S; Kagaya Y; Watanabe J; Shirato K
Circ J; 2005 Mar; 69(3):335-8. PubMed ID: 15731541
[TBL] [Abstract][Full Text] [Related]
20. Reversal of pulmonary hypertension and subsequent repair of atrial septal defect after treatment with continuous intravenous epoprostenol.
Frost AE; Quiñones MA; Zoghbi WA; Noon GP
J Heart Lung Transplant; 2005 Apr; 24(4):501-3. PubMed ID: 15797757
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
